{"drugs":["Halobetasol Propionate","Ultravate","Ultravate X"],"mono":{"0":{"id":"269200-s-0","title":"Generic Names","mono":"Halobetasol Propionate"},"1":{"id":"269200-s-1","title":"Dosing and Indications","sub":{"0":{"id":"269200-s-1-4","title":"Adult Dosing","mono":"<b>Inflammatory hyperkeratotic dermatosis:<\/b> apply cream or ointment TOPICALLY to affected area once or twice daily, MAX 50 g\/wk for 2 wk"},"1":{"id":"269200-s-1-5","title":"Pediatric Dosing","mono":"<ul><li>safety and effectiveness for children under age 12 y not established<\/li><li><b>Inflammatory hyperkeratotic dermatosis:<\/b> (12 y and older) apply cream or ointment TOPICALLY to affected area once or twice daily, MAX 50 g\/wk for 2 wk<\/li><\/ul>"},"3":{"id":"269200-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Inflammatory hyperkeratotic dermatosis<br\/>"}}},"3":{"id":"269200-s-3","title":"Contraindications\/Warnings","sub":[{"id":"269200-s-3-9","title":"Contraindications","mono":"hypersensitivity to any component of the product <br\/>"},{"id":"269200-s-3-10","title":"Precautions","mono":"<ul><li>age less than 12 years; use not recommended due to greater risk for adrenal suppression, Cushing syndrome, and intracranial hypertension in pediatric patients compared with adults<\/li><li>Cushing syndrome may occur from systemic absorption of topical corticosteroids<\/li><li>glucosuria may occur from systemic absorption of topical corticosteroids<\/li><li>hyperglycemia may occur from systemic absorption of topical corticosteroids<\/li><li>hypothalamic-pituitary-adrenal axis suppression has been reported; monitoring recommended; dosage adjustment, discontinuation, or drug substitution may be necessary<\/li><li>rosacea or perioral dermatitis; not recommended<\/li><\/ul>"},{"id":"269200-s-3-11","title":"Pregnancy Category","mono":"Halobetasol: C (FDA)<br\/>"},{"id":"269200-s-3-12","title":"Breast Feeding","mono":"Halobetasol: Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"5":{"id":"269200-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><br\/><b>Dermatologic:<\/b>Itching, Sensation of burning of skin, Stinging of skin<br\/><b>Serious<\/b><br\/><b>Endocrine metabolic:<\/b>Cushing's syndrome, Hypothalamic-pituitary-adrenal axis dysfunction<br\/>"},"6":{"id":"269200-s-6","title":"Drug Name Info","sub":{"0":{"id":"269200-s-6-17","title":"US Trade Names","mono":"<ul><li>Ultravate<\/li><li>Ultravate X<\/li><\/ul>"},"2":{"id":"269200-s-6-19","title":"Class","mono":"<ul><li>Adrenal Glucocorticoid<\/li><li>Corticosteroid, Very Strong<\/li><\/ul>"},"3":{"id":"269200-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"269200-s-6-21","title":"Generic Availability","mono":"Yes<br\/>"}}},"7":{"id":"269200-s-7","title":"Mechanism Of Action","mono":"Halobetasol propionate is a synthetic corticosteroid primarily used as an anti-inflammatory and antipruritic agent for topical use. It acts by inducing phospholipase A(2) inhibitory proteins known as lipocortins that control biosynthesis of potent mediators of inflammation which includes prostaglandins and leukotrienes, and thereby subsequently inhibiting the release of the precursor, arachidonic acid.<br\/>"},"8":{"id":"269200-s-8","title":"Pharmacokinetics","sub":[{"id":"269200-s-8-23","title":"Absorption","mono":"Bioavailability: less than 6% <br\/>"}]},"9":{"id":"269200-s-9","title":"Administration","mono":"<b>Topical<\/b><br\/><ul><li>apply thin layer to affected area and rub in gently and completely<\/li><li>do not use occlusive dressings unless otherwise directed by physician<\/li><li>do not apply to face, groin, or axillae<\/li><\/ul>"},"10":{"id":"269200-s-10","title":"Monitoring","mono":"<ul><li>reduced inflammation and pruritus<\/li><li>hypothalamic-pituitary-adrenal (HPA) axis suppression tests; periodically in patients applying medication to large or occluded areas or during prolonged therapy<\/li><\/ul>"},"11":{"id":"269200-s-11","title":"How Supplied","mono":"<ul><li><b>Generic<\/b><br\/><ul><li>Topical Cream: 0.05 %<\/li><li>Topical Ointment: 0.05 %<\/li><\/ul><\/li><li><b>Ultravate<\/b><br\/><ul><li>Topical Cream: 0.05 %<\/li><li>Topical Ointment: 0.05 %<\/li><\/ul><\/li><\/ul>"},"13":{"id":"269200-s-13","title":"Clinical Teaching","mono":"<ul><li>Tell patient to report signs\/symptoms of hypothalamic-pituitary-adrenal (HPA) axis suppression (fatigue, depression, anxiety, muscle weakness, immunosuppression), especially with prolonged use over large areas.<\/li><li>Drug may cause local stinging or burning, itching, erythema, rash, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, allergic contact dermatitis, and secondary infections.<\/li><li>Advise diabetic patient to report difficulties with glycemic control, as drug may cause hyperglycemia.<\/li><li>Counsel patient not to use an occlusive dressing unless directed to do so by a physician.<\/li><li>Advise patient to avoid application to the face, groin, or axillae.<\/li><\/ul>"}}}